European medical Journal. Urology最新文献_第8页

Findings and Implications of the REVEAL-CKD Study Investigating the Global Prevalence of Undiagnosed Stage G3 Chronic Kidney Disease 调查未确诊的G3期慢性肾脏疾病全球患病率的REVEAL-CKD研究的发现和意义

European medical Journal. Urology Pub Date : 2022-09-20 DOI: 10.33590/emj/10063690

N. Tangri, L. De Nicola

{"title":"Findings and Implications of the REVEAL-CKD Study Investigating the Global Prevalence of Undiagnosed Stage G3 Chronic Kidney Disease","authors":"N. Tangri, L. De Nicola","doi":"10.33590/emj/10063690","DOIUrl":"https://doi.org/10.33590/emj/10063690","url":null,"abstract":"Chronic kidney disease (CKD) is a progressive condition that can lead to \u0000kidney failure and the requirement for renal dialysis or transplantation. Early-stage \u0000CKD is often missed because the disorder is initially asymptomatic; hence, many \u0000patients with CKD already have symptomatic advanced disease (Stages G4–G5) \u0000at the time of diagnosis. This is an important issue because the drugs available \u0000for the treatment of CKD are most effective when given during the early stages of \u0000the disease (Stages G1–G3). EMJ conducted interviews in July 2022 with two key \u0000opinion leaders, Navdeep Tangri from the University of Manitoba, Winnipeg, Canada, \u0000and Luca De Nicola from the University of Campania Luigi Vanvitell, Naples, Italy, \u0000both of whom have a wealth of experience in the management of patients with CKD. \u0000The experts provided important insights into the ongoing REVEAL-CKD study, which \u0000was designed to explore the global prevalence of undiagnosed Stage G3 CKD. This \u0000article describes the main findings of the REVEAL-CKD study published to date and \u0000their implications. Possible approaches to improving the diagnosis of CKD are \u0000also discussed.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79202499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Novel Biomarkers and Drug Targets in Non-Small Cell Lung Cancer 非小细胞肺癌的新生物标志物和药物靶点

European medical Journal. Urology Pub Date : 2022-09-20 DOI: 10.33590/emj/10113934

Grace Dy

{"title":"Novel Biomarkers and Drug Targets in Non-Small Cell Lung Cancer","authors":"Grace Dy","doi":"10.33590/emj/10113934","DOIUrl":"https://doi.org/10.33590/emj/10113934","url":null,"abstract":"Despite therapeutic advances, the prognosis of non-small cell lung cancers (NSCLC) is still very poor, especially when first diagnosed at later stages involving metastases. NSCLC classification can be aided by identifying genetic, molecular, and histological subtypes that are important biomarkers in treatment selection. The majority of targeted therapies are now first-line treatment options for eligible patients with advanced stages of NSCLC. Here they have been shown to improve overall survival (OS) and progression free survival (PFS). Such treatments include those aimed at driver mutations in NSCLC, such as the genes for EGFR and ALK, and immune checkpoint inhibitors such as those targeting programmed death protein 1 or its ligand (programmed death ligand 1 [PD-L1]). In antibody-drug conjugates (ADC), cytotoxic payloads are conjugated to monoclonal antibodies (mAb) that deliver the drug to tumour cells expressing the corresponding target antigen. While there are still no ADCs specifically approved for NSCLC by the U.S. Food and Drugs Administration (FDA), several agents have shown promise and are being investigated as therapy in NSCLC. Emerging biomarkers as targets for ADCs with potential relevance in the treatment of NSCLC include products of the genes CEACAM5, TROP2, HER2, and c-MET. Herein, this interview provides an overview of biomarkers and targeted therapies, with a discussion with Grace Dy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA, on their potential clinical utility.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74287188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neratinib as a Potential Therapeutic for Mutant RAS and Osimertinib-Resistant Tumours 奈拉替尼作为突变RAS和奥西替尼耐药肿瘤的潜在治疗药物

European medical Journal. Urology Pub Date : 2022-09-20 DOI: 10.33590/emj/10197202

P. Dent, Laurence A Booth, A. Poklepovic, J. Hancock

{"title":"Neratinib as a Potential Therapeutic for Mutant RAS and Osimertinib-Resistant Tumours","authors":"P. Dent, Laurence A Booth, A. Poklepovic, J. Hancock","doi":"10.33590/emj/10197202","DOIUrl":"https://doi.org/10.33590/emj/10197202","url":null,"abstract":"Neratinib was developed as an irreversible catalytic inhibitor of ERBB2, which also acts to inhibit ERBB1 and ERBB4. Neratinib is U.S. Food and Drug Administration (FDA)-approved as a neo-adjuvant therapy for use in HER2+ breast cancer. More recently, chemical biology analyses and the authors’ own bench work have demonstrated that neratinib has additional targets, which open up the possibility of using the drug in cell types that either lack ERBB receptor family expression or who rely on survival signalling downstream of growth factor receptors. Neratinib rapidly disrupted mutant RAS nanoclustering, which was followed by mutant rat sarcoma virus proteins translocating via LC3-associated phagocytosis into the cytosol where they were degraded by macroautophagy. Neratinib catalytically inhibited the MAP4K mammalian STE20-like protein kinase 4 and also caused its degradation via macroautophagy. This resulted in ezrin dephosphorylation and the plasma membrane becoming flaccid. Neratinib disrupted the nanoclustering of RAC1, which was associated with dephosphorylation of PAK1 and Merlin, and with increased phosphorylation of the Merlin binding partners large tumour suppressor kinase 1/2, YAP, and TAZ. YAP and TAZ exited the nucleus. Neratinib retained its anti-tumour efficacy against NSCLC cells made resistant to either afatinib or to osimertinib. Collectively, these findings argue that the possibilities for the further development of neratinib as cancer therapeutic in malignancies that do not express or over-express members of the ERBB receptor family are potentially wide-ranging.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83008310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Interview: Yann Le Cam 采访:Yann Le Cam

European medical Journal. Urology Pub Date : 2022-09-20 DOI: 10.33590/emj/10118971

Y. le Cam

引用次数: 0

Seeing Is Believing: Invisibility Exacerbates Inequality for Patients Living with Rare Disease 眼见为实:隐形加剧了罕见疾病患者的不平等

European medical Journal. Urology Pub Date : 2022-09-20 DOI: 10.33590/emj/10149519

Darcy Richards

引用次数: 0

Marfan Syndrome and Autosomal Dominant Polycystic Kidney Disease: A Case of Rare Co-occurrence or Coincidence? 马凡氏综合征和常染色体显性多囊肾病:罕见的共同发生还是巧合?

European medical Journal. Urology Pub Date : 2022-09-20 DOI: 10.33590/emj/10008375

Arjun Sekar

{"title":"Marfan Syndrome and Autosomal Dominant Polycystic Kidney Disease: A Case of Rare Co-occurrence or Coincidence?","authors":"Arjun Sekar","doi":"10.33590/emj/10008375","DOIUrl":"https://doi.org/10.33590/emj/10008375","url":null,"abstract":"Background: Marfan syndrome (MFS) and autosomal dominant kidney disease (ADPKD) are two separate genetic disorders. The author describes the case of a young male with ADPKD who incidentally had Marfan-like features. A literature review was carried out to see if these two disorders could be linked.\u0000\u0000Case presentation: A young male presented for incidentally found renal cysts. Kidney function was well preserved, but the patient had positive family history of ADPKD. During routine follow-up, a history of aortic valve disease was mentioned. This, along with the patient’s tall, lean stature and long extremities raised the concern for MFS. A detailed physical examination and workup by other specialists confirmed a clinical diagnosis of MFS. They had no known family history of MFS. The patient has been followed at Associates in Kidney Care, Des Moines, Iowa, USA, for the past 2 years.\u0000\u0000Discussion: There are several reports of overlap of ADPKD and connective tissue disorders with an overlap of vascular disorders. ADPKD and MFS are caused by totally different mutations. However, the literature review showed that vascular abnormalities and connective tissue diseases may be more common with ADPKD. Studies have shown that there could be a common signalling pathway for connective tissue disorders when both genes are affected simultaneously. Further research is needed to identify these pathways. More frequent screening of vascular abnormalities might be warranted in those with both phenotypes.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75238425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tackling Unmet Medical Need: How Slow-Release Intra-articular Corticosteroids Could Play a Role in Improving Quality of Life and Reducing Risk in Osteoarthritis 解决未满足的医疗需求:缓释关节内皮质类固醇如何在改善生活质量和降低骨关节炎风险中发挥作用

European medical Journal. Urology Pub Date : 2022-09-20 DOI: 10.33590/emj/10023791

P. Conaghan, L. Simon

{"title":"Tackling Unmet Medical Need: How Slow-Release Intra-articular Corticosteroids Could Play a Role in Improving Quality of Life and Reducing Risk in Osteoarthritis","authors":"P. Conaghan, L. Simon","doi":"10.33590/emj/10023791","DOIUrl":"https://doi.org/10.33590/emj/10023791","url":null,"abstract":"Osteoarthritis (OA) is the fastest growing cause of disability worldwide, but, with few proven therapeutic options, it is an underserved condition. With increasingly ageing populations contributing to a rising global prevalence, this unmet need only threatens to worsen in the coming years. To date, researchers have tried and failed in their bids to develop new ways to treat the pain and loss of function that significantly impacts health-related quality of life (HrQoL) and leaves people vulnerable to accumulating disability and at risk of cardiovascular disease (CVD), comorbidities, and mortality. Now, a novel way to deliver one of the only proven interventions for pain and inflammation, corticosteroid injections, is on the horizon for knee OA. Slow-release formulations could possibly prolong the clinical benefit of a single injection from 6 weeks to 6 months, providing a new option to improve HrQoL for people with OA, and maybe even breaking the cycle of inflammation that likely contributes to progression.\u0000\u0000In this key opinion leader article, Philip Conaghan and Lee Simon discuss OA’s significant Quality of life (QoL) and long-term health impact. They also outline the current, inadequate treatment landscape, and explain how slow-release corticosteroids could potentially help tackle a huge unmet medical need.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83281653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in the Management of Acute and Recurrent Urinary Tract Infections Caused by Resistant Pathogens – What’s Next? 耐药病原体引起的急性和复发性尿路感染的治疗进展-下一步是什么?

European medical Journal. Urology Pub Date : 2022-09-20 DOI: 10.33590/emj/10081330

D. Fromer, V. Khullar, F. Wagenlehner

{"title":"Advances in the Management of Acute and Recurrent Urinary Tract Infections Caused by \u0000Resistant Pathogens – What’s Next?","authors":"D. Fromer, V. Khullar, F. Wagenlehner","doi":"10.33590/emj/10081330","DOIUrl":"https://doi.org/10.33590/emj/10081330","url":null,"abstract":"Uncomplicated urinary tract infections (uUTI) are one of the most common \u0000infections in the community, affecting >150 million people each year worldwide, and \u0000being responsible for large amounts of antibiotic prescribing.1,2 Up to 80% of females \u0000will experience at least one uUTI in their lifetime, and 45% will have recurrent uUTI.3\u0000The debilitating symptoms that accompany urinary tract infections (UTI), including \u0000pain and urinary urgency, coupled with the unpredictability of recurrence, negatively \u0000impact quality of life (QoL).1,3\u0000The GSK Industry Symposium took place on 1st July 2022 as part of the European \u0000Association of Urology (EAU) Conference in Amsterdam, the Netherlands, and \u0000focused on the challenges surrounding the diagnosis and management of uUTIs and \u0000recurrent UTIs in the context of increasing antimicrobial resistance. \u0000During the presentations, speakers Debra Fromer, Vik Khullar, and Florian \u0000Wagenlehner, all specialists in urology, outlined the challenges facing clinicians and \u0000patients in treating UTIs effectively whilst maintaining good antibiotic stewardship. \u0000The wide-ranging discussions included questions around differential diagnosis, \u0000personalised approaches to treatment, and the challenges of treating recurrent UTIs. \u0000The panel also discussed the need for new strategies to manage such infections, \u0000and highlighted alternatives to antibiotics that are under development and could \u0000help to slow the rise in antimicrobial resistance. The symposium finished on a \u0000positive note with discussions around new and emerging therapies, such as immune \u0000stimulation, vaccination, and fulguration, that could help many females to break the \u0000debilitating cycle of recurrent UTIs","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76345591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Management of Thrombosis in High-Risk Patients: Focus on Cancer-Associated Thrombosis 高危患者血栓形成的管理:重点关注癌症相关血栓形成

European medical Journal. Urology Pub Date : 2022-09-20 DOI: 10.33590/emj/10175843

M. Thomas, P. Bolton-Maggs, G. Agnelli

{"title":"Management of Thrombosis in High-Risk Patients: Focus on Cancer-Associated Thrombosis","authors":"M. Thomas, P. Bolton-Maggs, G. Agnelli","doi":"10.33590/emj/10175843","DOIUrl":"https://doi.org/10.33590/emj/10175843","url":null,"abstract":"This symposium took place during the International Society on Thrombosis and Haemostasis (ISTH) Congress, 2022. Ajay Kakkar, Thrombosis Research Institute, London, UK, opened the symposium by highlighting the extent to which patients with cancer are affected by thrombotic disease. Subsequently, Mari Thomas, University College London, UK, described the current treatment options for patients with cancer-associated thrombosis (CAT). Thomas highlighted the current unmet needs faced by these patients, with the risk of bleeding continuing to be the main issue affecting anticoagulation treatment. Paula Bolton-Maggs, University of Manchester, UK, and UK Haemovigilance Scheme, Manchester, UK, gave an overview of Factor XI (FXI) inhibition and outlined why this factor is a potential attractive anticoagulation drug target. Multiple therapies targeting FXI are currently in development, with seven clinical trials published to date.1-7 Although there are some similarities between these agents, there are also many differences in terms of their administration route and frequency, the timing of onset of action, and methods of metabolism and excretion. Giancarlo Agnelli, University of Perugia, Italy, and Istituti Clinici Scientifici (ICS) Maugeri, Pavia-Milan, Italy, then described the importance of conducting clinical trials that are designed to address the unmet needs of patients with CAT. In particular, he highlighted the ongoing Phase III ASTER and MAGNOLIA studies that are aiming to demonstrate that the FXI inhibitor abelacimab is superior to standard of care treatments in terms of bleeding rates for patients with CAT, including those with gastrointestinal (GI) or genitourinary (GU) tumours. Concluding remarks were given by Gary Raskob, University of Oklahoma Health Sciences Center, Oklahoma City, USA, who re-emphasised the unmet needs in the treatment of CAT, and the promise that FXI inhibitors hold for the future.","PeriodicalId":90162,"journal":{"name":"European medical Journal. Urology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75380895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review of the 11th European Conference on Rare Diseases and Orphan Products 2022 2022年第11届欧洲罕见病和孤儿产品会议综述

European medical Journal. Urology Pub Date : 2022-09-20 DOI: 10.33590/emj/10057417

引用次数: 0